UY25779A1 - Procedimiento para la preparación de una forma anhidra de clorhidrato de valaciclovir - Google Patents
Procedimiento para la preparación de una forma anhidra de clorhidrato de valaciclovirInfo
- Publication number
- UY25779A1 UY25779A1 UY25779A UY25779A UY25779A1 UY 25779 A1 UY25779 A1 UY 25779A1 UY 25779 A UY25779 A UY 25779A UY 25779 A UY25779 A UY 25779A UY 25779 A1 UY25779 A1 UY 25779A1
- Authority
- UY
- Uruguay
- Prior art keywords
- valacyclovir
- hydrochloride
- crystalline form
- valacyclovir hydrochloride
- anhydrous crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere a un procedimiento para preparar una forma cristalina anhidra del clorohidrato del L-valinato del (2-[2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi] etilo, conocida como clorohidrato de valaciclovir, que posee una potente actividad antiviral y se usa ampliamente en el tratamiento y profilaxis de infecciones virales en humanos, particularmente infecciones causadas por el grupo del virus del herpes. Se proporciona un procedimiento para la producción del clorhidrato de valaciclovir en una forma cristalina anhidra que incluye substancialmente una configuración del espaciado d (en Angstroms) determinada. El procedimiento se caracteriza porque comprende los siguientes pasos: a) formar el valaciclovir en solución ya sea en la base libre o en la forma de la sal; b) convertir el valaciclovir de la base libre o la sal del mismo al clorhidrato de valaciclovir; c) aislar el clorhidrato de valaciclovir de la solución y opcionalmente remover el solvente no unido, dejando el clorhidrato de valaciclovir en la forma substancialmente seca; d) tratar el clorhidrato de valaciclovir con 15% a 40% p/p de un alcohol inferior que tiene 1 a 4 átomos de carbono o de una cetona inferior que contiene desde 3 hasta 6 átomos de carbono que sirve para convertir una cantidad del clorhidrato del valaciclovir secado opcionalmente en la forma cristalina anhidra; y e) aislar la forma cristalina anhidra. El solvente es preferiblemente un solvente orgánico soluble an agua, que debe ser los suficientemente solubilizante y debe ser empleado en una cantidad que permita la solubilización parcial para efectuar la conversión y la precipitación, por ejemplo de la forma cristalina hidratada hasta la forma cristalina anhidra deseada del clorhidrato del valaciclovir. Preferiblemente el solvente orgánico es un alcohol, ventajosamente un alcohol inferior que contiene 1 a 4 átomos de carbono (etanol o un solvente compuesto substancialmente de etanol), o una cetona inferior que contiene 3 a 6 átomos de carbono y contiene agua (acetona acuosa con un contenido de agua de 6% hasta 12% en peso aproximadamente). En un segundo aspecto de la invención se proporciona un clorhidrato de valaciclovir que tiene un contenido de agua de hidratación de no más de 3% en peso (p/p).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9501178.9A GB9501178D0 (en) | 1995-01-20 | 1995-01-20 | Guanine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25779A1 true UY25779A1 (es) | 2000-08-21 |
Family
ID=10768347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25779A UY25779A1 (es) | 1995-01-20 | 1999-10-29 | Procedimiento para la preparación de una forma anhidra de clorhidrato de valaciclovir |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US6107302A (es) |
| EP (1) | EP0804436B1 (es) |
| JP (1) | JP3176633B2 (es) |
| KR (1) | KR100376074B1 (es) |
| CN (1) | CN1049893C (es) |
| AP (1) | AP662A (es) |
| AR (1) | AR002270A1 (es) |
| AT (1) | ATE302777T1 (es) |
| AU (1) | AU702794B2 (es) |
| BG (1) | BG63393B1 (es) |
| BR (1) | BR9606768A (es) |
| CA (1) | CA2210799C (es) |
| CY (1) | CY2531B1 (es) |
| CZ (1) | CZ297065B6 (es) |
| DE (1) | DE69635106T2 (es) |
| DK (1) | DK0804436T3 (es) |
| EA (1) | EA000364B1 (es) |
| EE (1) | EE03528B1 (es) |
| ES (1) | ES2248806T3 (es) |
| FI (1) | FI973063A (es) |
| GB (1) | GB9501178D0 (es) |
| GE (1) | GEP20001940B (es) |
| HR (1) | HRP960024B1 (es) |
| HU (1) | HU222993B1 (es) |
| IL (1) | IL116831A (es) |
| IN (1) | IN182468B (es) |
| IS (1) | IS2268B (es) |
| NO (1) | NO315558B1 (es) |
| NZ (1) | NZ298851A (es) |
| OA (1) | OA10499A (es) |
| PL (1) | PL182175B1 (es) |
| RO (1) | RO118693B1 (es) |
| RS (1) | RS49518B (es) |
| SI (1) | SI0804436T1 (es) |
| SK (1) | SK285329B6 (es) |
| TR (1) | TR199700656T1 (es) |
| UA (1) | UA46001C2 (es) |
| UY (1) | UY25779A1 (es) |
| WO (1) | WO1996022291A1 (es) |
| ZA (1) | ZA96449B (es) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501178D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Guanine derivative |
| DK0874631T3 (da) * | 1996-01-19 | 2004-03-22 | Glaxo Group Ltd | Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse |
| IT1283447B1 (it) * | 1996-07-18 | 1998-04-21 | Ind Chimica Srl | Processo di preparazione del valaciclovir e relativi intermedi |
| AU5495898A (en) * | 1997-01-17 | 1998-08-07 | Ajinomoto Co., Inc. | Novel z-valacyclovir crystals |
| GB0010446D0 (en) * | 2000-04-28 | 2000-06-14 | Glaxo Wellcome Kk | Pharmaceutical formulation |
| HU230382B1 (hu) * | 2001-02-24 | 2016-03-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként |
| SK1592004A3 (sk) * | 2001-09-07 | 2005-03-04 | Teva Pharmaceutical Industries Ltd. | Kryštalické formy valaciklovírus hydrochlóridu |
| EP1453834A1 (en) * | 2001-11-05 | 2004-09-08 | Glaxo Group Limited | Anhydrous crystal form of valaciclovir hydrochloride |
| MX242714B (es) * | 2001-11-14 | 2006-12-15 | Teva Pharma | Sintesis y purificacion de valaciclovir. |
| WO2004000265A2 (en) * | 2002-06-24 | 2003-12-31 | Ranbaxy Laboratories Limited | Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US20050043329A1 (en) * | 2002-09-06 | 2005-02-24 | Shlomit Wizel | Crystalline forms of valacyclovir hydrochloride |
| US20050059684A1 (en) * | 2002-10-16 | 2005-03-17 | Ben-Zion Dolitzky | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| ATE335743T1 (de) * | 2002-10-16 | 2006-09-15 | Teva Pharma | Verfahren zur verminderung von restalkoholen im kristallinen valacyclovir-hydrochlorid |
| WO2004052892A1 (en) * | 2002-12-09 | 2004-06-24 | Texcontor Etablissement | Anhydrous crystalline form of valacyclovir hydrochloride |
| US7786302B2 (en) * | 2003-05-30 | 2010-08-31 | Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. | Crystalline forms of valacyclovir hydrochloride |
| KR100871621B1 (ko) * | 2003-06-02 | 2008-12-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 발라시클로비르 히드로클로라이드의 신규한 결정질 형태 |
| CA2552560A1 (en) * | 2004-01-21 | 2005-08-11 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of valacyclovir hydrochloride |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| JP2008504255A (ja) * | 2004-06-30 | 2008-02-14 | テバ ファーマシューティカル インダストリーズ リミティド | 結晶塩酸バラシクロビル中の残留アルコールを低減する方法 |
| DE102004054054A1 (de) * | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| US20060178512A1 (en) * | 2005-02-04 | 2006-08-10 | Cheruthur Govindan | Method for preparing amino acid esters of nucleoside analogues |
| WO2006127217A2 (en) * | 2005-05-25 | 2006-11-30 | Eli Lilly And Company | Cyclopropanecarboxylate esters of acyclovir |
| EP1746098A1 (en) * | 2005-07-21 | 2007-01-24 | SOLMAG S.p.A. | Valacyclovir polymorphs and a process for the preparation thereof |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20070112193A1 (en) * | 2005-11-14 | 2007-05-17 | Khunt Mayur D | Valacyclovir process |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| NZ619413A (en) | 2006-05-04 | 2015-08-28 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
| CN1903854B (zh) * | 2006-08-09 | 2012-05-23 | 丽珠医药集团股份有限公司 | 一种合成盐酸伐昔洛韦的方法 |
| US20080167325A1 (en) * | 2006-12-27 | 2008-07-10 | Bs Praveen Kumar | Valacyclovir compositions |
| US20080281099A1 (en) * | 2007-05-07 | 2008-11-13 | Mayur Devjibhai Khunt | Process for purifying valacyclovir hydrochloride and intermediates thereof |
| GB0710277D0 (en) * | 2007-05-30 | 2007-07-11 | Univ Birmingham | Use of antivirals in the treatment of medical disorders |
| ES2733348T3 (es) * | 2007-08-17 | 2019-11-28 | Boehringer Ingelheim Int | Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP |
| JPWO2009031576A1 (ja) * | 2007-09-03 | 2010-12-16 | 味の素株式会社 | バラシクロビル塩酸塩結晶の製造方法 |
| US20090076039A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched valacyclovir |
| AR071175A1 (es) * | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| CA2735562C (en) * | 2008-08-15 | 2017-10-17 | Boehringer Ingelheim International Gmbh | Dpp-4 inhibitors for wound healing |
| RU2011113823A (ru) | 2008-09-10 | 2012-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療 |
| BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
| WO2011158252A1 (en) | 2010-06-15 | 2011-12-22 | Matrix Laboratories Ltd | Process for the preparation of valacyclovir hydrochloride polymorphic form ii |
| EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| CN102584825B (zh) * | 2011-01-17 | 2014-04-02 | 四川科伦药物研究有限公司 | 一种合成盐酸伐昔洛韦的方法 |
| CN103781788B (zh) | 2011-07-15 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 经取代的喹唑啉、其制备及其在药物组合物中的用途 |
| WO2013076688A1 (en) * | 2011-11-25 | 2013-05-30 | Piramal Enterprises Limited | A process for the preparation of valacyclovir hydrochloride |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
| CN110437231B (zh) * | 2019-09-04 | 2022-04-29 | 上药康丽（常州）药业有限公司 | 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法 |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP160A (en) * | 1987-08-15 | 1991-11-18 | The Wellcome Foundation Ltd | Therapeutic acyclic nucleosides. |
| ES2157259T3 (es) * | 1993-06-10 | 2001-08-16 | Rolabo Sl | Procedimiento para preparar esteres de aminoacidos y analogos de nucleosidos. |
| GB9501178D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Guanine derivative |
-
1995
- 1995-01-20 GB GBGB9501178.9A patent/GB9501178D0/en active Pending
-
1996
- 1996-01-19 RO RO97-01334A patent/RO118693B1/ro unknown
- 1996-01-19 NZ NZ298851A patent/NZ298851A/xx not_active IP Right Cessation
- 1996-01-19 EP EP96900631A patent/EP0804436B1/en not_active Expired - Lifetime
- 1996-01-19 CZ CZ0229497A patent/CZ297065B6/cs not_active IP Right Cessation
- 1996-01-19 PL PL96321326A patent/PL182175B1/pl not_active IP Right Cessation
- 1996-01-19 US US08/875,173 patent/US6107302A/en not_active Expired - Lifetime
- 1996-01-19 AP APAP/P/1997/001058A patent/AP662A/en active
- 1996-01-19 IL IL11683196A patent/IL116831A/en not_active IP Right Cessation
- 1996-01-19 HU HU9801836A patent/HU222993B1/hu not_active IP Right Cessation
- 1996-01-19 CA CA002210799A patent/CA2210799C/en not_active Expired - Fee Related
- 1996-01-19 HR HR960024A patent/HRP960024B1/xx not_active IP Right Cessation
- 1996-01-19 BR BR9606768A patent/BR9606768A/pt active IP Right Grant
- 1996-01-19 AT AT96900631T patent/ATE302777T1/de not_active IP Right Cessation
- 1996-01-19 DK DK96900631T patent/DK0804436T3/da active
- 1996-01-19 UA UA97084268A patent/UA46001C2/uk unknown
- 1996-01-19 RS YU3396A patent/RS49518B/sr unknown
- 1996-01-19 WO PCT/GB1996/000117 patent/WO1996022291A1/en active IP Right Grant
- 1996-01-19 GE GEAP19963845A patent/GEP20001940B/en unknown
- 1996-01-19 AR ARP960101082A patent/AR002270A1/es not_active Application Discontinuation
- 1996-01-19 EE EE9700175A patent/EE03528B1/xx not_active IP Right Cessation
- 1996-01-19 IN IN102MA1996 patent/IN182468B/en unknown
- 1996-01-19 TR TR97/00656T patent/TR199700656T1/xx unknown
- 1996-01-19 SI SI9630717T patent/SI0804436T1/sl unknown
- 1996-01-19 JP JP52213196A patent/JP3176633B2/ja not_active Expired - Fee Related
- 1996-01-19 DE DE69635106T patent/DE69635106T2/de not_active Expired - Lifetime
- 1996-01-19 EA EA199700124A patent/EA000364B1/ru not_active IP Right Cessation
- 1996-01-19 SK SK965-97A patent/SK285329B6/sk not_active IP Right Cessation
- 1996-01-19 ES ES96900631T patent/ES2248806T3/es not_active Expired - Lifetime
- 1996-01-19 KR KR1019970704916A patent/KR100376074B1/ko not_active IP Right Cessation
- 1996-01-19 AU AU44539/96A patent/AU702794B2/en not_active Ceased
- 1996-01-19 CN CN96192662A patent/CN1049893C/zh not_active Expired - Fee Related
- 1996-01-19 ZA ZA96449A patent/ZA96449B/xx unknown
-
1997
- 1997-07-15 IS IS4527A patent/IS2268B/is unknown
- 1997-07-16 OA OA70051A patent/OA10499A/en unknown
- 1997-07-18 NO NO19973326A patent/NO315558B1/no not_active IP Right Cessation
- 1997-07-18 FI FI973063A patent/FI973063A/fi not_active Application Discontinuation
- 1997-08-14 BG BG101833A patent/BG63393B1/bg unknown
-
1999
- 1999-10-29 UY UY25779A patent/UY25779A1/es not_active IP Right Cessation
-
2005
- 2005-11-16 CY CY0500061A patent/CY2531B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25779A1 (es) | Procedimiento para la preparación de una forma anhidra de clorhidrato de valaciclovir | |
| KR890003761A (ko) | 치료학적 아시클릭 뉴클레오시드 | |
| AR041679A1 (es) | Compuestos polimorfos de mesilato de imatinib | |
| PE49296A1 (es) | Procedimiento para preparar clorhidrato de 1-(2`-desoxi-2',2'-difluoro-d-ribofuranosil)-4-aminopirimidin-2-ona | |
| BR0210333A (pt) | catalisador de rutênio, processos para preparar o mesmo e álcoois de açúcar por hidrogenação catalìtica dos monossacarìdeos e oligossacarìdeos correspondentes, e, uso de um catalisador | |
| AR051778A2 (es) | Derivados del acido dimetilaminocrotonico y procesos para supreparacion | |
| ES2170732B2 (es) | Procedimiento para preparar citalopram purificado | |
| KR880012605A (ko) | 피라졸로[3,4-d]피리미딘, 이들의 제조방법 및 이들을 함유하는 제약조성물 | |
| CA2330007C (en) | Improvements in macrolide production | |
| DK1412083T3 (da) | Fremgangsmåde til fremstilling af sorbitol ved hydrogenering af egnede monosaccharider på en Ru/Sio2-katalysator | |
| CA2364251A1 (en) | Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs | |
| CO4750651A1 (es) | Compuesto activo farmacologicamente | |
| ES2270172T3 (es) | Procedimiento para reducir alcoholes residuales en hidrocloruro de valaciclovir cristalino. | |
| AR027559A1 (es) | Metodo para la preparacion de citalopram | |
| ES2163117T3 (es) | Procedimiento para la preparacion de derivados de purinas. | |
| AR240878A2 (es) | Un procedimiento para preparar un silicato de aluminio cristalino compuesto | |
| CO5210865A1 (es) | Proceso para la produccion de los acidos 2-fenilamino-5-aceticos | |
| PE20000271A1 (es) | Composicion farmaceutica de (1s,4r)-cis-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]-2-ciclopenteno-1-metanol | |
| BR1101133A (pt) | Derivado de sinergistina, (quinuclidinil-3(s) tiometil-5 bem como seus sais farmaceuticamente aceitáveis, processo de preparação do derivado de sinergistina e composição farmacêutica | |
| RU2003110580A (ru) | Способ очистки правастатина | |
| PT84819B (pt) | Processo para a preparacao de compostos 2-piridil-penem | |
| MXPA04006391A (es) | Procesos para preparar calcio de mupirocina cristalina y amorfa. | |
| ECSP014079A (es) | Derivados de sulfonamida | |
| MX169972B (es) | Procedimieto para purificar acido 2-hidroxinaftalin-6-carboxilico | |
| AR016733A1 (es) | Procedimiento de preparacion de 4-(3-piridinil)-1h-imidazol, y los compuestos intermedios empleados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VENC | Patent expired |
Effective date: 20191029 |